Treatment Details – 15.0 months

Survival: 15.0 months
Toxicity Grade:3
Treatments: Immunotherapy
Drugs: Proleukin
City/State/Province:Casale Monferrato
Hospital:Ospedale S. Spirito
Date: 2/2001

Patients: This Phase II study involved 31 patients with malignant pleural mesothelioma.

Treatment: The treatment consisted of the injection of human recombinant Interleukin-2 (Proleukin).

Toxicity: Grade 3 toxicities included cardiac failure and fever. Grade 2 toxicities included neuropathy, neurologic, and gastrointestinal.

Results: Median overall survival was 15 months.

Correspondence: Bruno Castagneto, MD

Get your free copy of
“Surviving Mesothelioma” Today!